|Bid||2.05 x 1400|
|Ask||2.12 x 400|
|Day's range||2.04 - 2.15|
|52-week range||0.78 - 4.25|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.50|
On a per-share basis, the Montreal-based company said it had a loss of 61 cents. Losses, adjusted for non-recurring costs, came to 44 cents per share. The drug developer posted revenue of $241,000 in the ...
Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies, today reported financial and operating results for the third quarter ended September 30, 2017.
Aeterna Zentaris Inc. will announce its third quarter 2017 financial and operating results after market close on Wednesday, November 8, 2017.